1. Home
  2. VCNX

VCNX

Vaccinex Inc.

Logo Vaccinex Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.

Founded: 2001 Country:
United States
United States
Employees: N/A City: ROCHESTER
Market Cap: 10.8M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 12.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -43.68 EPS Growth: N/A
52 Week Low/High: $5.87 - $100.80 Next Earning Date: 05-13-2024
Revenue: $570,000 Revenue Growth: 107.27%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: